[1]袁绍斌,曹小萌,夏天红,等.胃癌临床病理特征与HER2表达的相关性研究[J].医学信息,2022,35(24):50-54.[doi:10.3969/j.issn.1006-1959.2022.24.010]
　YUAN Shao-bin,CAO Xiao-meng,XIA Tian-hong,et al.Correlation Between Clinicopathological Features and HER2 Expression in Gastric Cancer[J].Journal of Medical Information,2022,35(24):50-54.[doi:10.3969/j.issn.1006-1959.2022.24.010]
点击复制

胃癌临床病理特征与HER2表达的相关性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年24期
页码:
50-54
栏目:
论著
出版日期:
2022-12-15

文章信息/Info

Title:
Correlation Between Clinicopathological Features and HER2 Expression in Gastric Cancer
文章编号:
1006-1959（2022）24-0050-05
作者:
袁绍斌; 曹小萌; 夏天红; 等
（1.甘肃中医药大学第一临床医学院，甘肃 兰州 730000；2.解放军联勤保障部队第九四〇医院普通外科，甘肃 兰州 730050；3.甘肃省干细胞与基因药物重点实验室，甘肃 兰州 730050；4.兰州大学第二医院普通外科三病区，甘肃 兰州 730030）
Author(s):
YUAN Shao-bin; CAO Xiao-meng; XIA Tian-hong; et al.
(1.The First Clinical Medical College of Gansu University of Chinese Medicine,Lanzhou 730000,Gansu,China;2.Department of General Surgery,the 940th Hospital of Joint Logistics Support Force of the Chinese People’s Liberation Army,Lanzhou 730050,Gansu,Chi
关键词:
胃癌; 人表皮生长因子受体-2; 靶向药物
Keywords:
Gastric cancer; Human epidermal growth factor receptor-2; Targeted drugs
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2022.24.010
文献标志码:
A
摘要:
目的 分析胃癌患者中影响人表皮生长因子受体-2（HER2）阳性表达率的危险因素及临床意义。方法 收集2019年1月-2020年12月就诊于兰州大学第二医院行胃癌外科手术切除的101例患者临床资料，根据HER2的表达程度将无着色和（+）设为HER2阴性组、（++）和（+++）设为HER2阳性组。比较两组临床特征，并应用二元Logistic回归分析影响HER2表达的独立危险因素。结果 101例胃癌患者中HER2阳性35例，阳性率为34.65%；HER2表达与年龄、肿瘤大小、分化程度、Lauren分型、TNM分期有关（P＜0.05），与性别、肿瘤位置、浸润深度、淋巴结是否转移、脉管、神经是否侵犯无关（P＞0.05）；在血常规及肿瘤标志物方面，HER2表达与CEA、AFP、CA-199、CA-125、血红蛋白、白蛋白、白细胞、血小板无关（P＞0.05）；通过二元Logistic回归分析显示，年龄、肿瘤大小、TNM分期是影响HER2表达的危险因素（P＜0.05）。结论 HER2的表达与患者年龄、肿瘤大小、TNM分期、分化程度、Lauren分型具有相关性，通过测定胃癌组织中HER2蛋白的表达，有助于判断患者预后，也可为分子靶向治疗药物在胃癌的应用提供理论依据。
Abstract:
Objective To analyze the risk factors influencing the positive expression rate of human epidermal growth factor receptor 2 (HER2) in gastric cancer patients and its clinical significance.Methods The clinical data of 101 patients who underwent surgical resection of gastric cancer in the Lanzhou University Second Hospital from January 2019 to December 2020 were collected. According to the expression of HER2, no staining and (+) were set as HER2 negative group, (++) and (+++) were set as HER2 positive group. The clinical characteristics of the two groups were compared, and the independent risk factors affecting HER2 expression were analyzed by binary Logistic regression.Results Of the 101 patients with gastric cancer, 35 were HER2 positive, with a positive rate of 34.65%. The expression of HER2 was related to age, tumor size, differentiation, Lauren classification and TNM stage (P<0.05), was not related to gender, tumor location, depth of invasion, lymph node metastasis, vascular and nerve invasion (P>0.05). In terms of blood routine and tumor markers, the expression of HER2 was not related to CEA, AFP, CA-199, CA-125, hemoglobin, albumin, white blood cells and platelets (P>0.05). Binary Logistic regression analysis showed that age, tumor size and TNM stage were risk factors affecting HER2 expression (P<0.05).Conclusion The expression of HER2 is correlated with age, tumor size, TNM stage, differentiation degree and Lauren classification. By measuring the expression of HER2 protein in gastric cancer tissues, it is helpful to judge the prognosis of patients, and also provides a theoretical basis for the application of molecular targeted therapy drugs in gastric cancer.

参考文献/References:

[1]Sexton RE,Al Hallak MN,Diab M,et al.Gastric cancer:a comprehensive review of current and future treatment strategies[J].Cancer Metastasis Rev,2020,39(4):1179-1203.[2]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.[3]陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13.[4]Rawla P,Barsouk A.Epidemiology of gastric cancer: global trends, risk factors and prevention[J].Prz Gastroenterol,2019,14(1):26-38.[5]Pellat A,Vaquero J,Fouassier L.Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology[J].Hepatology,2018,67(2):762-773.[6]Ajani JA,D’Amico TA,Bentrem DJ,et al.Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(2):167-192.[7]Nagpal P,Prakash A,Pradhan G,et al.MDCT imaging of the stomach: advances and applications[J].Br J Radiol,2017,90(1069):20160412.[8]Meric-Bernstam F,Johnson AM,Dumbrava EEI,et al.Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer[J].Clin Cancer Res,2019,25(7):2033-2041.[9]Lordick F,Janjigian YY.Clinical impact of tumour biology in the management of gastroesophageal cancer[J].Nat Rev Clin Oncol,2016,13(6):348-360.[10]Buza N,Hui P.Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma[J].Arch Pathol Lab Med,2022,146(5):0.[11]Wang N,Mei Q,Wang Z,et al.Research Progress of Antibody-Drug Conjugate Therapy for Advanced Gastric Cancer[J].Front Oncol,2022,12:889017.[12]Connell CM,Doherty GJ.Activating HER2 mutations as emerging targets in multiple solid cancers[J].ESMO Open,2017,2(5):e000279.[13]Mahtani R,Kittaneh M,Kalinsky K,et al.Advances in Therapeutic Approaches for Triple-Negative Breast Cancer[J].Clin Breast Cancer,2021,21(5):383-390.[14]Antonacopoulou AG,Tsamandas AC,Petsas T,et al.EGFR, HER-2 and COX-2 levels in colorectal cancer[J].Histopathology,2008,53(6):698-706.[15]Afify AM,Werness BA,Mark HF.HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma[J].Exp Mol Pathol,1999,66(2):163-169.[16]Xiao Y,Ding J,Ma D,et al.Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer[J].Front Immunol,2022,13:877825.[17]Egebjerg K,Garbyal RS,Hasselby JP,et al.Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis[J].Crit Rev Oncol Hematol,2021,161:103339. [18]Hartman ZC,Wei J,Osada T,et al.An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity[J].Clin Cancer Res,2010,16(5):1466-1477.[19]Dhritlahre RK,Saneja A.Recent advances in HER2-targeted delivery for cancer therapy[J].Drug Discov Today,2021,26(5):1319-1329.[20]Van Cutsem E,Feyereislova A,张信华.曲妥珠单抗联合化疗与单纯化疗治疗HER2阳性晚期胃或胃食管结合部癌的Ⅲ期、开放、随机对照临床试验(ToGA试验)[J].消化肿瘤杂志(电子版),2010,2(3):128.[21]Van Cutsem E,Bang YJ,Feng-Yi F,et al.HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer[J].Gastric Cancer,2015,18(3):476-484.[22]彭强,余昌俊.Her-2蛋白、PGⅡ及Sema4D蛋白在胃癌组织中的表达及临床意义[J].分子诊断与治疗杂志,2021,13(11):1875-1878,1883.[23]Pinto-de-Sousa J,David L,Almeida R,et al.c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma[J].Int J Surg Pathol,2002,10(4):247-256.[24]Ozen A,Tatar G.The relationship between HER2 expression and 18F-FDG in gastric carcinoma[J].Hell J Nucl Med,2022,25(1):5-10.[25]Uprak TK,Attaallah W,?覶elikel ?覶A,et al.HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters[J].Ulus Cerrahi Derg,2015,31(4):207-213.[26]Janjigian YY,Werner D,Pauligk C,et al.Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis[J].Ann Oncol,2012,23(10):2656-2662.[27]Matsusaka S,Nashimoto A,Nishikawa K,et al.Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)[J].Gastric Cancer,2016,19(3):839-851.[28]Lau-Min KS,Li Y,Eads JR,et al.Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma[J].Cancer,2022,128(9):1853-1862.[29]Zhao H,Huang C,Lin M,et al.Dynamic detection of HER2 of circulating tumor cells in patients with gastric carcinoma and its clinical application[J].Mol Med Rep,2022,25(5):187.

相似文献/References:

[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,31(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
　YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Journal of Medical Information,2018,31(24):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小华,等.基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J].医学信息,2018,31(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
　RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Journal of Medical Information,2018,31(24):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化疗并发嗜血细胞综合征患者的护理[J].医学信息,2018,31(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
　DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Journal of Medical Information,2018,31(24):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理会,李育庄,李春辉.胃癌与高凝血状态关系的研究现状[J].医学信息,2018,31(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
　PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Journal of Medical Information,2018,31(24):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(24):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[6]林跃韩,许庆文.腹腔镜uncut Roux-en-Y吻合与传统吻合方式的研究进展[J].医学信息,2018,31(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
　LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Journal of Medical Information,2018,31(24):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[7]马玉涛,石文娜,李晓林,等.免疫荧光法检测FSHR与GnRHR在胃癌组织中的分布及其共定位研究[J].医学信息,2018,31(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
　MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Journal of Medical Information,2018,31(24):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[8]赵 静.血浆纤维蛋白原和CA724水平在胃癌患者的变化及临床意义[J].医学信息,2018,31(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
　ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Journal of Medical Information,2018,31(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
[9]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
　WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Journal of Medical Information,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
[10]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,32(01):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
　NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Journal of Medical Information,2019,32(24):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]

更新日期/Last Update: 1900-01-01